This is the authors' abstract. We don't add key points for this paper.
A concise synthesis of AMN107, a compound currently undergoing several phase II/III clinical trials for chronic myelogenous leukemia is described. The new procedure reduces the number of synthetic steps from eight to four, with an overall yield of 65%.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: